乳腺癌类器官的培养及鉴定

doi:10.16352/j.issn.1001-6325.2024.09.1223

基础医学与临床 ›› 2024, Vol. 44 ›› Issue (9): 1223-1228.doi: 10.16352/j.issn.1001-6325.2024.09.1223

• 特邀专题：类器官及其芯片 • 上一篇下一篇

乳腺癌类器官的培养及鉴定

夏雨佳, 杨振丽, 代娣, 刘玉琴^*

中国医学科学院基础医学研究所北京协和医学院基础学院病理学系,北京 100005

收稿日期:2024-06-26 修回日期:2024-07-11 出版日期:2024-09-05 发布日期:2024-08-30
通讯作者: ^*liuyuqin@pumc.edu.cn
基金资助:
中国医学科学院医学与健康科技创新工程-重大协同创新项目(2021-I2M-1-053)

Culture and characterization of breast cancer organoids

XIA Yujia, YANG Zhenli, DAI Di, LIU Yuqin^*

Department of Pathology, Institute of Basic Medical Sciences CAMS, School of Basic Medicine PUMC, Beijing 100005, China

Received:2024-06-26 Revised:2024-07-11 Online:2024-09-05 Published:2024-08-30
Contact: ^*liuyuqin@pumc.edu.cn

摘要/Abstract

摘要： 目的建立乳腺癌类器官并长期培养,鉴定其相关分子特征及对相关药物的敏感性。方法乳腺癌患者手术标本,胶原酶消化法,获取细胞进行类器官培养,进行形态学观察,免疫荧光检测ER、PR、HER-2、CK表达,对其中3例类器官进行紫杉醇、多柔比星、顺铂药敏测试。结果共培养建立了44例乳腺癌类器官,均呈实性类球状生长。类器官ER、PR、HER-2、CK表达情况与患者临床样品一致。乳腺癌类器官对化疗药紫杉醇、多柔比星、顺铂具有一定敏感性。结论乳腺癌类器官作为新型体外模型,具有一定异质性,再现体内病生理功能特性。

关键词: 乳腺癌, 类器官, 药敏实验

Abstract: Objective To establish breast cancer organoids for a long time and to characterize their molecular expression and test their sensitivity to chemotherapy drugs. Methods Breast cancer specimens were digested with collagenase to release cancer cells for organoid culture. The organoids were characterized by morphology and ER,PR,HER-2,CK expression by technology of histoimmunofluorescence. Among them, three were tested for paclitaxel, doxorubicin and cisplatin sensitivity. Results A total of 44 cases of breast cancer organoids were established, all of which showed dense spherical-like growth and ER,PR,HER-2,CK, matching their clinical counterpart. Breast cancer organoids were sensitive to chemotherapy drugs paclitaxel, doxorubicin and cisplatin. Conclusions Organoid model, as a new in vitro may reproduce the pathophysiology features with heterogeneity.

Key words: breast cancer, organoid, drug sensitive test

中图分类号:

R737.9

夏雨佳, 杨振丽, 代娣, 刘玉琴. 乳腺癌类器官的培养及鉴定[J]. 基础医学与临床, 2024, 44(9): 1223-1228.

XIA Yujia, YANG Zhenli, DAI Di, LIU Yuqin. Culture and characterization of breast cancer organoids[J]. Basic & Clinical Medicine, 2024, 44(9): 1223-1228.

参考文献 10

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024,74:229-263.
[2]	Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours[J]. Nature, 2000,406:747-752.
[3]	Marcotte R, Sayad A, Brown KR, et al. Functional genomic landscape of human breast cancer drivers, vulnerabilities, and resistance[J]. Cell, 2016,164:293-309.
[4]	Razavi P, Chang MT, Xu G, et al. The genomic landscape of endocrine-resistant advanced breast cancers[J]. Cancer Cell, 2018,34:427-438.
[5]	Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response[J]. Nature,2013,501:346-354.
[6]	Namekawa T, Ikeda K, Horie-Inoue K,et al. Application of prostate cancer models for preclinical study: advantages and limitations of cell lines, patient-derived xenografts, and three-dimensional culture of patient-derived cells[J]. Cells, 2019,8:74. doi: 10.3390/cells8010074.
[7]	Sachs N, de Ligt J, Kopper O, et al. A living biobank of breast cancer organoids captures disease heterogeneity[J]. Cell, 2018,172:373-386.
[8]	Lancaster MA, Renner M, Martin CA, et al. Cerebral organoids model human brain development and microcephaly[J]. Nature, 2013, 501:373-379.
[9]	Hendriks D, Brouwers JF, Hamer K, et al. Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis[J]. Nat Biotechnol, 2023,41:1567-1581.
[10]	Castiglione H, Vigneron PA, Baquerre C, et al. Human brain organoids-on-chip: advances, challenges, and perspectives for preclinical applications[J]. Harmaceutics,2022,14:2301. doi: 10.3390/pharmaceutics14112301.

[1]	李彬凤, 吕发友, 易辉君, 吕侣. 环指蛋白家族在乳腺癌中作用机制的研究进展[J]. 基础医学与临床, 2026, 46(1): 124-128.
[2]	金晓霞, 刘玉山, 胡继平, 朱兴华. COA6在乳腺癌中的表达及其与肿瘤免疫细胞浸润相关[J]. 基础医学与临床, 2025, 45(6): 755-761.
[3]	王盟, 沈学静, 刘佳, 尚璐璐, 张沫. 基于探针的无标记表面增强拉曼光谱(SERS)用于鉴别乳腺癌患者的血清代谢谱[J]. 基础医学与临床, 2025, 45(5): 651-657.
[4]	张柯, 陆江宁, 孙立新, 遇珑, 孙力超, 冉宇靓. TOMM40L促进三阴性乳腺癌细胞增殖和迁移并与不良预后相关[J]. 基础医学与临床, 2025, 45(5): 575-582.
[5]	王晨曦, 杨淑春, 贾玉艳, 黄粤. 利用人多能干细胞衍生的肝细胞样类器官构建肝脏再生的研究模型[J]. 基础医学与临床, 2025, 45(5): 589-598.
[6]	果月红, 周凡琦, 吴熙, 张冠南, 王芳, 余佳. 利用结直肠癌类器官模型评估化疗药物药效[J]. 基础医学与临床, 2025, 45(4): 456-464.
[7]	郝思嘉, 杨振丽, 卞晓翠, 侯昱宏, 刘玉琴. Luc2-tdT标记的小鼠肝癌细胞系的建立及鉴定[J]. 基础医学与临床, 2025, 45(3): 317-322.
[8]	罗钰蓓, 黄建军, 杨文秀, 张军红, 李静, 赵春华, 豆晓伟. 4株患者原代细胞源的乳腺癌细胞系建立及初步研究[J]. 基础医学与临床, 2025, 45(2): 183-188.
[9]	张彦池, 施俊琦, 张一君, 段佳文, 刘进宇, 张丽燕, 梁晚平. 乳腺癌代谢机制与免疫微环境靶向的协同治疗进展[J]. 基础医学与临床, 2025, 45(12): 1662-1667.
[10]	苏凌峰, 王虎霞, 王延峰, 宋张骏. 慢性压力对乳腺癌发展的影响[J]. 基础医学与临床, 2024, 44(9): 1303-1307.
[11]	杨振丽, 夏雨佳, 刘玉琴. 器官芯片——更具前景的体外模型[J]. 基础医学与临床, 2024, 44(9): 1202-1207.
[12]	夏雨佳, 杨振丽, 刘玉琴. 肿瘤类器官临床前转化研究及应用[J]. 基础医学与临床, 2024, 44(9): 1214-1218.
[13]	王靓, 夏隆阔, 张建民. 脑类器官在药物研发中的研究进展[J]. 基础医学与临床, 2024, 44(9): 1208-1213.
[14]	刘保清, 黄容, 卢艳, 李凯, 张宁, 刘长征, 宋伟. 胃癌类器官在基础研究与临床应用中的进展[J]. 基础医学与临床, 2024, 44(9): 1219-1222.
[15]	朱宛宛, 周金娟, 修建波. 小分子化合物组合改善多能干细胞向脑类器官定向分化的效率[J]. 基础医学与临床, 2024, 44(6): 786-792.

乳腺癌类器官的培养及鉴定

Culture and characterization of breast cancer organoids

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 10

相关文章 15

编辑推荐

Metrics

本文评价